Lord’s Mark Industries Outlines MedTech Expansion and Strong Multi-Year Growth Guidance
Lords Mark Industries Ltd · Investor Presentation · 12 Sept 2026, 6:03 pm
Lord’s Mark Industries Outlines MedTech Expansion and Strong Multi-Year Growth Guidance Lord’s Mark Industries provided FY27 guidance projecting consolidated revenue of ₹1,550 crore with ~21% EBITDA margin and ~13.25% PAT margin, led by MedTech (₹825 crore). For FY28, revenue is targeted to cross ₹2,100 crore with EBITDA margins expanding to 23–24%. The firm plans ₹300–350 crore in capex over three years, including an IVD plant in Lucknow and in-house dialysis manufacturing. Operating cash flow is expected to turn positive in FY27. To meet MPS norms, promoters will dilute 4–5% via OFS and equity.
Original exchange filing (PDF)
More announcements from Lords Mark Industries Ltd
- Investor Presentation H1 · 18 Nov 2026
- Investor Meet on 19th Nov 2026 · 16 Nov 2026
- Revised Outcome of BM held on 14 Nov 2026 · 15 Nov 2026
- Revised financials for September 2026 · 15 Nov 2026
- Outcome of Board Meeting held on 14.11.2026 · 14 Nov 2026
- September 2026 results · 14 Nov 2026
- Lords Mark Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Board Meeting intimation .... · 14 Nov 2026
- Dr. Sachidanand Upadhyay , MD has featured in TIME magazine for third consecutive years . · 03 Nov 2026
